Burfeind William R, Glower Donald D, Davis R Duane, Landolfo Kevin P, Lowe James E, Wolfe Walter G
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Ann Thorac Surg. 2002 Oct;74(4):S1323-5. doi: 10.1016/s0003-4975(02)03909-7.
In reoperation for mitral valve disease, minimally invasive Port-Access (PORT) is a new alternative to standard median sternotomy (STER) or right thoracotomy (THOR); yet, the results of PORT in this setting have not been defined. The aim of this study was to evaluate the results of minimally invasive thoracotomy in reoperation for mitral valve disease.
Retrospective results are reported for three consecutive series of patients undergoing reoperation for mitral disease using either PORT (n = 60, 1996 to 2001), THOR (n = 37, 1985 to 1997), or STER (n = 155, 1985 to 1997).
Red cell transfusion was 3 +/- 4, 14 +/- 13, and 12 +/- 12 units for PORT, THOR, and STER, respectively. Chest tube output was 352 +/- 361, 2048 +/- 3166, and 1683 +/- 3939 mL, respectively. Cardiopulmonary bypass times for these groups were 208 +/- 76 vs. 158 +/- 56 vs. 157 +/- 53 minutes. Thirty-day mortality was 0/60 (0%), 8/37 (22%), and 21/155 (14%), respectively.
This early clinical experience suggests that PORT is an acceptable alternative to THOR or STERN in reoperation for mitral valve disease, with potential advantages of avoiding redo sternotomy and reducing the surgical incision. However, these benefits may come at the expense of longer cardiopulmonary bypass times.
在二尖瓣疾病再次手术中,微创端口入路(PORT)是标准正中胸骨切开术(STER)或右胸切开术(THOR)的一种新的替代方法;然而,PORT在这种情况下的结果尚未明确。本研究的目的是评估二尖瓣疾病再次手术中微创开胸手术的结果。
报告了连续三组二尖瓣疾病再次手术患者的回顾性结果,分别采用PORT(n = 60,1996年至2001年)、THOR(n = 37,1985年至1997年)或STER(n = 155,1985年至1997年)。
PORT、THOR和STER组的红细胞输注量分别为3±4、14±13和12±12单位。胸腔闭式引流量分别为352±361、2048±3166和1683±3939毫升。这些组的体外循环时间分别为208±76分钟、158±56分钟和157±53分钟。30天死亡率分别为0/60(0%)、8/37(22%)和21/155(14%)。
这一早期临床经验表明,在二尖瓣疾病再次手术中,PORT是THOR或STER的一种可接受的替代方法,具有避免再次胸骨切开术和减少手术切口的潜在优势。然而,这些益处可能是以更长的体外循环时间为代价的。